<?xml version="1.0" encoding="UTF-8"?>
<ref id="B54-molecules-25-00942">
 <label>54.</label>
 <element-citation publication-type="confproc">
  <person-group person-group-type="author">
   <name>
    <surname>Gatell</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Raffi</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Plettenberg</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Portilla</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Hoffmann</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Arasteh</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Teppler</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Doravirine 100 mg QD vs Efavirenz + TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results</article-title>
  <source>Proceedings of the Conference on Retroviruses and Opportunistic Infections</source>
  <conf-loc>Boston, MA, USA</conf-loc>
  <conf-date>22â€“25 February 2016</conf-date>
  <comment>abstract number 470</comment>
 </element-citation>
</ref>
